Web of Science: 3 citations, Scopus: 3 citations, Google Scholar: citations,
Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation
Masip, Jenifer (Hospital Universitari Joan XXIII de Tarragona)
Jorba, Rosa (Hospital Universitari Joan XXIII de Tarragona)
López Dupla, Jesús Miguel (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau)
Pacheco, Yolanda María (Laboratorio de Inmunología. Instituto de Biomedicina de Sevilla. Hospital Universitario Virgen del Rocío. Consejo Superior de Investigaciones Científicas (Espanya). Universidad de Sevilla)
García-Pardo, Graciano (Hospital Universitari Joan XXIII de Tarragona)
Martínez, Esteban (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Viladés, Consuelo (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Veloso, Sergi (Hospital Universitari Joan XXIII de Tarragona)
Alba, Verónica (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Olona, Montserrat (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Vidal, Francesc (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Gómez-Bertomeu, Frederic (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Peraire, Joaquim (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)
Rull, Anna (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas)

Date: 2022
Abstract: Nuclear magnetic resonance (NMR)-based advanced lipoprotein tests have demonstrated that LDL and HDL particle numbers (LDL-P and HDL-P) are more powerful cardiovascular (CV) risk biomarkers than conventional cholesterol markers. Of interest, in people living with HIV (PLHIV), predictors of preclinical atherosclerosis and vascular dysfunction may be associated with impaired immune function. We previously stated that immunological non-responders (INR) were at higher CV risk than immunological responders (IR) before starting antiretroviral therapy (ART). Using Liposcale tests, we characterized the lipoprotein profile from the same cohort of PLHIV at month 12 and month 36 after starting ART, intending to explore what happened with these indicators of CV risk during viral suppression. ART initiation dissipates the differences in lipoprotein-based CV risk markers between INR and IR, and only an increase in the number of HDL-P was found in INR + IR when compared to controls (p = 0. 047). Interestingly, CD4 T-cell counts negatively correlated with medium HDL-P concentrations at month 12 in all individuals (ρ = −0. 335, p = 0. 003). Longitudinal analyses showed an important increase in LDL-P and HDL-P at month 36 when compared to baseline values in both IR and INR. A proper balance between a proatherogenic and atherogenic environment may be related to the reconstitution of CD4 T-cell count in PLHIV.
Grants: Instituto de Salud Carlos III PI16/00503
Instituto de Salud Carlos III PI19/01337
Instituto de Salud Carlos III PI20/00326
Instituto de Salud Carlos III RD16/0025/0006
Instituto de Salud Carlos III CB21/13/00020
Instituto de Salud Carlos III INT20/00031
Instituto de Salud Carlos III CP19/00146
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR948
Note: Altres ajuts: European Regional Development Fund/European Social Fund, "A way to make Europe"/"Investing in your future"; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas; Universitat Rovira i Virgili (2019PMF-PIPF-18), Martí Franquès Research Fellowship Programme; IISPV (project "2019/IISPV/05", Boosting Young Talent); GeSIDA (III Premio para Jóvenes Investigadores 2019).
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès
Document: Article ; recerca ; Versió publicada
Subject: Antiretroviral therapy ; Cardiovascular risk ; Immunological non-responder ; Lipoproteins ; Longitudinal analysis ; Nuclear magnetic resonance ; People living with HIV
Published in: International journal of molecular sciences, Vol. 23 Núm. 15 (august 2022) , p. 8071, ISSN 1422-0067

DOI: 10.3390/ijms23158071
PMID: 35897644


12 p, 3.0 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles

 Record created 2023-10-05, last modified 2024-04-12



   Favorit i Compartir